PG490-88, a derivative of triptolide, attenuates obliterative airway disease in a mouse heterotopic tracheal allograft model

  • J Heart Lung Transplant. 2002 Dec;21(12):1314-8. doi: 10.1016/s1053-2498(02)00449-7.
Colm T Leonard  1 ,  Paola M Soccal ,  Gerald J Berry ,  Ramona L Doyle ,  James Theodore ,  Steven R Duncan ,  Glenn D Rosen
Affiliations
  • 1. Division of Pulmonary and Critical Care Medicine, Department of Histopathology, Stanford University Medical Center, Stanford, California, USA. [email protected]
PMID: 12490278 DOI: 10.1016/s1053-2498(02)00449-7
Abstract

The current treatment of obliterative bronchiolitis in lung transplant recipients is sub-optimal. Triptolide is a novel immunosuppressant that has a mechanism of action distinct from currently available immunosuppressants, including induction of T-cell Apoptosis, blockade of fibroblast proliferation/maturation and inhibition of transforming growth factor-beta (TGF-beta) mRNA production. We hypothesized that triptolide may be helpful in blocking obliterative airway disease in lung transplant recipients. We investigated the effect of PG490-88, a water-soluble derivative of triptolide, in a mouse heterotopic tracheal allograft model of obliterative airway disease. We show that PG490-88 attenuates airway obliteration in this model and inhibits accumulation of inflammatory cells, and therefore may have preventive or therapeutic benefits for patients with obliterative airway disease (OAD) following lung transplantation.

Products